Similarly, Zheng et al., showed that the co-administration of c-MET-targeted CAR-M with gemcitabine or irinotecan amplified antitumour effects in pancreatic cancer models (100), suggesting that certain chemotherapeutics may remodel the TME in ways that enhance macrophage infiltration and persistence. This evidence concerns the gene MET and familial pancreatic carcinoma.